Castle Biosciences Celebrates TissueCypher Approval in New York for Esophageal Cancer Risk Assessment

Castle Biosciences Achieves Milestone with TissueCypher Approval in New York

Castle Biosciences, Inc., a leading precision medicine company based in Friendswood, Texas, celebrates a significant achievement with the full assay approval of its TissueCypher Barrett's Esophagus test by the New York State Department of Health (NYSDOH). This milestone positions TissueCypher as the first AI-driven test specifically designed to assess the risk of progression from Barrett's esophagus (BE) to esophageal cancer. The approval signals a commitment to enhancing patient care through advanced molecular testing, reflecting the company’s mission to provide innovative diagnostic solutions. Kristen Oelschlager, Chief Operating Officer, emphasizes that this development underscores Castle’s dedication to delivering high-quality diagnostic tools that can lead to better patient outcomes.

The TissueCypher test is particularly valuable given the alarming statistics surrounding esophageal cancer, which has a rising incidence rate and a low five-year survival rate of only 22%. Approximately 5% of adults in the U.S. are affected by Barrett's esophagus, a condition that can arise from chronic acid reflux and serves as the sole known precursor to esophageal cancer. Derek Maetzold, Castle’s Chief Executive Officer, highlights that this approval broadens access to a test that evaluates cancer-associated biomarkers and spatial biology. This comprehensive analysis allows healthcare providers to make informed decisions regarding patient surveillance and potential early interventions, ultimately aiming to improve survival rates among patients predisposed to this aggressive cancer.

The clinical validity of the TissueCypher test is reinforced by 14 peer-reviewed studies, showcasing its efficacy in predicting the progression of Barrett's esophagus. Additionally, in March 2022, the test received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services (CMS), further establishing its importance in the clinical landscape. This approval from NYSDOH not only enhances the test's accessibility in New York but also emphasizes Castle Biosciences' ongoing commitment to pioneering diagnostic innovations that prioritize patient health and well-being.

In other relevant developments, Castle Biosciences continues to advocate for the integration of advanced diagnostic tools in clinical practice. The company’s focus on molecular testing is indicative of a broader trend within the healthcare industry, where precision medicine is increasingly becoming a cornerstone of effective patient care. Through its ongoing research and development initiatives, Castle aims to expand its portfolio of tests that address unmet medical needs and improve patient outcomes.

Castle Biosciences invites interested parties to learn more about its innovative diagnostics and ongoing commitment to enhancing patient care by visiting their official website at www.CastleBios.